Gulf Pharmaceutical Industries
Gulf Pharmaceutical Industries manufactures and distributes pharmaceutical products across regional and international markets. The company generates revenue through medicine production and sales, supported by healthcare demand.
Growth metrics compare to the same period one year earlier (YoY). Quarters use same-quarter prior year.
The 7 checklist categories use Fundamentals Checklist ratings. Growth columns are YoY (membership required). All ratio metrics are unlocked for everyone.
Scroll the list or search. Up to 15 peers. Choices stay on this device.
Select Period
Select your metrics
Reports & Analysis
Reports & Analysis
Financial Highlights
Financial Highlights summarize key positive trends and watch points identified from the company’s financial data.Free cash flow has been negative for 2 consecutive quarters.
Net income increased while operating cash flow declined in the latest year.
Net income increased while free cash flow declined in the latest year.
Operating cash flow has declined for 2 consecutive quarters.
Free cash flow has declined for 2 consecutive quarters.
Cash conversion is weak — operating cash flow covers less than 70% of net income.
Operating cash flow margin has declined for 2 consecutive quarters.
Net income remains more than 20% below its historical peak.
No dividend history available for this company yet.
| # | Holder | % of Holding | Shares Held | Date Reported |
|---|---|---|---|---|
| 1 | Middle East Pharma for Investments | 24.09% | 279,444,000 | Oct 10, 2026 |
| 2 | Ras Al Khaimah Government | 12.24% | 141,984,000 | Oct 10, 2026 |
| 3 | Yasser bin Yousef bin Mohammed Naghi | 9% | 104,400,000 | Oct 10, 2026 |
| 4 | Mohammed Abdulaziz Rabie Shaheen Al Muhairi | 7.58% | 87,928,000 | Oct 10, 2026 |
| 5 | (Arab Company for Pharmaceutical Industries and Medical Supplies (ACDIMA) | 6.19% | 71,804,000 | Oct 10, 2026 |
| 6 | Sheikh Faisal bin Saqr bin Mohammed Al Qasimi | 5.65% | 65,540,000 | Oct 10, 2026 |
